SCHEMBL1474285

SCHEMBL1474285

CC(=O)N1CCN(CCNC(=O)c2cc(-c3ccco3)on2)CC1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.64
NPC1 O15118 8/20 0.64
ALDH1A1 P00352 8/20 0.64
SMN1; SMN2 Q16637 6/20 0.64
LMNA P02545 4/20 0.64
HPGD P15428 3/20 0.64
TP53 P04637 1/20 0.64
GAA P10253 1/20 0.64
HTT P42858 4/20 0.56
KMT2A Q03164 3/20 0.54
MAPT P10636 2/20 0.52
TSHR P16473 2/20 0.52
MAPK1 P28482 2/20 0.51
MEN1 O00255 2/20 0.51
KDM4E B2RXH2 2/20 0.51
HSD17B10 Q99714 1/20 0.51
PKM P14618 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1477101 0.90 RAB9A (0.67) RAB9ANPC1ALDH1A1SMN1; SMN2LMNA
SCHEMBL27176294 0.88 RAB9A (0.67) RAB9ANPC1ALDH1A1SMN1; SMN2LMNA
SCHEMBL1475232 0.87 RAB9A (0.65) RAB9ANPC1ALDH1A1SMN1; SMN2LMNA
SCHEMBL1474419 0.86 LMNA (0.72) RAB9ANPC1ALDH1A1SMN1; SMN2LMNA
SCHEMBL1474268 0.85 RAB9A (0.63) RAB9ANPC1ALDH1A1SMN1; SMN2LMNA
SCHEMBL1474960 0.84 ALDH1A1 (0.64) RAB9ANPC1ALDH1A1SMN1; SMN2LMNA
SCHEMBL1476629 0.84 ALDH1A1 (0.62) RAB9ANPC1ALDH1A1SMN1; SMN2LMNA
SCHEMBL15190130 0.84 HPGD (0.47) RAB9ANPC1ALDH1A1SMN1; SMN2LMNA
SCHEMBL1475249 0.84 RAB9A (0.58) RAB9ANPC1ALDH1A1SMN1; SMN2LMNA
SCHEMBL1474506 0.82 ALDH1A1 (0.58) RAB9ANPC1ALDH1A1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-7915297-B2 Isoxazole derivatives and use thereof SK HOLDINGS CO., LTD. (KR) 2011-03-29 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 RAB9A 2013/4885NPC1 2242/4885ALDH1A1 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.